Novogene Europe Bolsters European Sequencing Power with Fifth NovaSeq X Plus Platform
London, UK – July 3, 2025 – Novogene Europe, a leading provider of comprehensive genomic services, is pleased to announce a significant expansion of its European sequencing capabilities with the installation of its fifth NovaSeq X Plus platform. This strategic investment underscores Novogene’s commitment to meeting the growing demand for high-throughput, accurate, and cost-effective sequencing solutions across the continent.
The NovaSeq X Plus, developed by Illumina, represents a cutting-edge advancement in sequencing technology, offering unprecedented throughput, exceptional data quality, and enhanced efficiency. By adding this fifth platform to its European operations, Novogene Europe is poised to further solidify its position as a premier genomics service provider, capable of supporting a wide range of research and clinical applications.
This expansion will directly benefit researchers and clinicians across Europe by providing increased capacity and faster turnaround times for critical projects. The NovaSeq X Plus platform is particularly well-suited for large-scale genome sequencing, including whole-genome sequencing (WGS), whole-exome sequencing (WES), and RNA sequencing (RNA-Seq), enabling deeper insights into disease mechanisms, drug discovery, and personalized medicine.
“We are thrilled to announce the deployment of our fifth NovaSeq X Plus platform in Europe,” said [Insert Name and Title of Novogene Europe Spokesperson, if available from the original press release. If not, use a general title like “a spokesperson for Novogene Europe”]. “This significant investment reflects our dedication to providing our European partners with state-of-the-art technology and superior service. The enhanced capabilities of the NovaSeq X Plus will empower our clients to accelerate their research, drive innovation, and ultimately contribute to advancements in human health.”
Novogene Europe has established a strong reputation for its commitment to quality, reliability, and customer support. The addition of the fifth NovaSeq X Plus platform will further enhance these attributes, allowing for more extensive collaborations and the processing of larger, more complex genomic datasets.
This strategic expansion is a testament to Novogene Europe’s proactive approach in anticipating and responding to the evolving needs of the European life sciences sector. With an increased capacity for high-throughput sequencing, Novogene Europe is well-equipped to support groundbreaking discoveries and contribute to the growing genomic landscape in Europe.
About Novogene:
Novogene is a leading global genomics service company, providing comprehensive, high-quality, and cost-effective genomic sequencing and analysis services to researchers and clinicians worldwide. With a commitment to innovation and customer satisfaction, Novogene empowers scientific discovery and advancements in human health.
Media Contact:
[Insert Media Contact Information if available from the original press release]
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Novogene Europe amplía sus capacidades de secuenciación con la quinta plataforma NovaSeq X Plus en Europa’ at 2025-07-03 09:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.